Intervention of Interest
- semaglutide (Wegovy®, Novo Nordisk)
For questions please contact [email protected].
View the Key Stakeholder List.
- tirzepatide (Zepbound®, Eli Lilly and Company)
Obesity Management
An assessment of semaglutide and tirzepatide
Public Meeting
November 2025
Assessment Status
Open
Upcoming Milestone
Evidence ReportView
Main Review
November 13, 2025
New England CEPAC
The New England CEPAC’s 2025 public meeting on semaglutide and tirzepatide
Register for Meeting
Public Comment Period
See Full Timeline
09/09/2025 - 10/06/2025
Public Comments on Draft Evidence Report
Related Assessments & Policy Papers.
Obesity Management
Sep 2022Obesity Management
Jul 2015
09/09/2025
Draft Evidence Report
10/29/2025
Evidence Report
11/13/2025
Evidence Presentation
12/16/2025
Public Comments
OpenView
Closed